BELSOMRA Drug Patent Profile

When do Belsomra patents expire, and when can generic versions of Belsomra launch?

Belsomra is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-five patent family members in thirty-six countries.

The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this compound. Additional details are available on the suvorexant profile page.

DrugPatentWatch^® Generic Entry Outlook for Belsomra

Belsomra was eligible for patent challenges on August 13, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 29, 2033. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

There is one tentative approval for the generic drug (suvorexant), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for BELSOMRA

International Patents:	75
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	35
Clinical Trials:	34
Patent Applications:	443
Drug Prices:	Drug price information for BELSOMRA
What excipients (inactive ingredients) are in BELSOMRA?	BELSOMRA excipients list
DailyMed Link:	BELSOMRA at DailyMed

See drug prices for BELSOMRA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BELSOMRA

NDA:

204569

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BELSOMRA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts General Hospital	PHASE4
Massachusetts Institute of Technology	PHASE4
Merck Sharp & Dohme LLC	Phase 2

See all BELSOMRA clinical trials

Pharmacology for BELSOMRA

Drug Class	Orexin Receptor Antagonist
Mechanism of Action	Cytochrome P450 3A Inhibitors Orexin Receptor Antagonists P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for BELSOMRA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BELSOMRA	Tablets	suvorexant	5 mg, 10 mg, 15 mg and 20 mg	204569	1	2024-03-04

US Patents and Regulatory Information for BELSOMRA

BELSOMRA is protected by four US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-001	Aug 13, 2014		RX	Yes	No			Y	Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-002	Aug 13, 2014		RX	Yes	No			Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-001	Aug 13, 2014		RX	Yes	No			Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-003	Aug 13, 2014		RX	Yes	No			Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-002	Aug 13, 2014		RX	Yes	No			Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-004	Aug 13, 2014		RX	Yes	Yes			Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-004	Aug 13, 2014		RX	Yes	Yes			Y

International Patents for BELSOMRA

When does loss-of-exclusivity occur for BELSOMRA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Japan

Mexico

Russian Federation

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BELSOMRA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2013267613
Australia	2018201279
Brazil	112014025041	composição farmacêutica
Canada	2795550	FORMES PHARMACEUTIQUES POSOLOGIQUES SOLIDES D'UN ANTAGONISTE DES RECEPTEURS DES OREXINES (SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST)
China	104321059	Solid dosage formulations of an orexin receptor antagonist
China	109078015	食欲素受体拮抗剂的固体剂量制剂 (Solid dosage formulations of an orexin receptor antagonist)
European Patent Office	2854816	FORMULATIONS PHARMACEUTIQUES SOLIDES D'UN ANTAGONISTE DE RÉCEPTEUR D'OREXINE (SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST)

Belsomra Market Dynamics, Patent Exclusivity, and Financial Trajectory

Last updated: August 19, 2026

Belsomra, Merck’s suvorexant insomnia drug, has established a durable commercial position in the orexin antagonist segment but remains exposed to generic erosion and newer branded competitors. Its sales trajectory has been supported by differentiated mechanism, physician familiarity, and expansion of the insomnia market. Long-term growth is constrained by generic availability, competing dual-orexin receptor antagonists, payer pressure, and the absence of a broad new indication base.

What is Belsomra and how does it work?

Belsomra is the brand name for suvorexant, an oral dual orexin receptor antagonist approved for the treatment of insomnia characterized by difficulties with sleep onset, sleep maintenance, or both.

The FDA approved Belsomra in August 2014. Merck commercializes the product in the United States, while licensing and regional commercialization arrangements have supported distribution in selected international markets. Belsomra is available in 5 mg, 10 mg, 15 mg, and 20 mg tablets. The recommended starting dose is generally 10 mg, with a maximum recommended dose of 20 mg once per night.[1]

Unlike zolpidem and other sedative-hypnotics, suvorexant suppresses wake-promoting orexin signaling rather than acting primarily through gamma-aminobutyric acid pathways. The product’s label includes warnings concerning next-day impairment, complex sleep behaviors, worsening depression, sleep paralysis, cataplexy-like symptoms, and compromised respiratory function in susceptible patients.[1]

FDA regulatory status

Milestone	Date
FDA approval	Aug. 13, 2014
Initial indication	Insomnia with sleep-onset or sleep-maintenance difficulty
Dosage forms	Oral tablets
Strengths	5 mg, 10 mg, 15 mg, 20 mg
Regulatory pathway	New drug application
Therapeutic class	Dual orexin receptor antagonist

Belsomra does not have the regulatory profile of a biologic. Biosimilar litigation and biologic interchangeability rules do not apply. The principal future threat is an abbreviated new drug application, or ANDA, for generic suvorexant.

How has Belsomra’s financial trajectory developed?

Belsomra generated a gradual commercial ramp after its 2014 launch. Adoption benefited from the clinical need for alternatives to older hypnotics and from the product’s differentiated mechanism. Growth has been slower than the initial opportunity suggested because insomnia treatment is heavily genericized and physicians commonly use low-cost zolpidem, eszopiclone, trazodone, and off-label agents.

Merck’s public reporting does not consistently disclose Belsomra as a standalone line item in recent annual filings. The product is generally grouped within broader pharmaceutical or other-product categories. This limits direct verification of current annual revenue from company filings.

Commercial trajectory

Period	Market position and financial interpretation
2014-2016	Launch phase, formulary development, and physician education
2017-2019	Expansion in the branded insomnia market; increasing prescription familiarity
2020-2021	Continued demand, but exposure to generic sleep medicines and COVID-era prescribing changes
2022-2024	Mature branded product with continued sales, offset by newer orexin competitors and patent-risk concerns
2025 onward	Growth depends on retention, pricing, international sales, and timing of generic entry

Belsomra is commercially meaningful to Merck but is not a core revenue driver at the scale of Keytruda, Gardasil, Januvia, or other major franchises. Its value is better assessed as a specialty primary-care asset with recurring prescription demand than as a blockbluster product capable of materially changing Merck’s consolidated growth rate.

The key financial variables are net price, insurance coverage, refill persistence, direct-to-consumer promotion, and the speed of substitution after generic launch. Because insomnia therapy is often chronic or recurrent, Belsomra has a refill-based revenue model. That model supports recurring revenue but also creates a large substitution pool once a lower-priced generic becomes available.

What patents protect Belsomra?

Belsomra’s protection is based principally on patents covering suvorexant, related orexin receptor antagonist compounds, pharmaceutical compositions, and methods of treatment. The relevant patent estate can include compound, formulation, dosage, and method-of-use claims.

Public patent databases identify several U.S. patents associated with suvorexant and orexin antagonist technology, including patents assigned to Merck or related Merck entities. The principal U.S. patent family associated with suvorexant has been cited in connection with protection extending into the late 2020s, while later patents may extend certain claim coverage into approximately 2030, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and Orange Book listing status.[2][3]

Principal protection categories

Protection category	Commercial relevance
Active pharmaceutical ingredient	Protects suvorexant itself or closely defined chemical classes
Salt, crystal, or solid-state form	Can restrict manufacturing and substitution using a claimed form
Pharmaceutical composition	Covers tablet compositions and excipient combinations
Dosage regimen	May cover selected strengths, timing, or patient use
Method of treatment	Protects use in treating insomnia or sleep-maintenance disorders
Manufacturing process	Can increase the cost and complexity of generic production

Patent expiration cannot be determined from the earliest compound patent alone. The commercial loss-of-exclusivity date depends on which patents are listed in the FDA Orange Book, whether an ANDA applicant files a Paragraph IV certification, whether the listed patents survive litigation, and whether pediatric or patent-term extensions apply.

When does Belsomra lose exclusivity?

Belsomra’s regulatory exclusivity has already expired. The remaining barrier is patent exclusivity.

The 2014 approval provided five years of new chemical entity exclusivity. That period prevented the FDA from approving an ANDA referencing suvorexant until the statutory exclusivity period ended. The relevant five-year period has passed, so generic applicants can pursue ANDA approval subject to patent certifications and other FDA requirements.[4]

The practical U.S. generic-entry window is likely governed by patent expiry in the late 2020s rather than by FDA regulatory exclusivity. Later Orange Book-listed patents could delay entry into or beyond 2030 if they are valid, enforceable, and successfully asserted.

Generic-entry scenarios

Scenario	Expected commercial effect
No successful Paragraph IV challenge before final patent expiry	Belsomra remains protected until the relevant patent barrier ends
Paragraph IV litigation with settlement	Entry may occur on a negotiated date before nominal patent expiry
Patent invalidation or non-infringement ruling	Earlier generic launch and rapid price erosion
Authorized generic launch	Merck may retain part of the post-entry value chain
Multiple generic entrants	Faster price compression and greater pharmacy substitution

What is the Orange Book status of Belsomra?

Belsomra is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The Orange Book is the controlling public source for listed patents, expiration dates, pediatric extensions, and certain exclusivity information.[4]

The relevant patent record should be reviewed by product strength and dosage form because an ANDA applicant may certify differently against compound, formulation, or method-of-use patents. Method-of-use patents can be addressed through a section viii statement when the generic label omits the protected indication, although the commercial scope of that strategy depends on the precise labeling and claim language.

An Orange Book listing does not prove that a patent will withstand litigation. It creates a statutory framework for certification, notice, and potential litigation. A Paragraph IV notice can trigger a 30-month stay of FDA approval if the NDA holder files a qualifying infringement action within the statutory period.[5]

Which companies are challenging Belsomra?

No major publicly established Belsomra generic litigation campaign has become a defining market event comparable to the challenges against high-revenue oncology or cardiovascular products. Generic manufacturers can still file ANDAs and Paragraph IV certifications without creating an immediate commercial launch.

Potential ANDA participants include large generic manufacturers such as Teva, Viatris, Sandoz, Lupin, Zydus, Sun Pharma, and Dr. Reddy’s, but a company should not be treated as a confirmed Belsomra challenger without an FDA filing, Paragraph IV notice, court docket, or public settlement.

The litigation risk is therefore asymmetric. A single successful challenge could shorten the protected commercial period, while the absence of public litigation does not guarantee that generic applications have not been filed.

How strong is the Belsomra patent estate?

Belsomra has a moderate-to-strong estate for a small-molecule insomnia product, but its strength depends on claim breadth and the remaining life of the core compound patents.

Strengths

• The product has an identifiable active ingredient with clinical and commercial differentiation.
• Compound and composition claims can present substantial barriers to direct substitution.
• The FDA-approved product has several strengths and a well-defined oral dosage form.
• Merck has substantial litigation and regulatory resources.

Vulnerabilities

• The product is a small molecule, making ANDA competition structurally easier than biosimilar competition.
• Generic applicants can attack patents through invalidity and non-infringement arguments.
• Some method-of-use claims may be avoidable through label carve-outs.
• Insomnia treatment has substantial generic substitution pressure.
• Clinical differentiation may not support a large premium after generic entry.

The estate is commercially valuable because it protects a recurring prescription product, but it is unlikely to maintain premium pricing after multiple generic entrants.

What formulations and methods of use are protected?

Belsomra’s relevant protection may cover tablet compositions, defined doses, treatment of insomnia, and administration designed to improve sleep onset or maintenance. Formulation patents have greater commercial value when they cover a necessary physical form or manufacturing feature rather than an easily designed-around excipient combination.

Method-of-use patents can protect treatment of selected patient populations or sleep-related endpoints. Their value is lower when the generic label can omit the patented use while still receiving approval for an unpatented indication.

Suvorexant also has manufacturing and process-related intellectual property. These rights can complicate generic development but rarely prevent entry if an alternative process is available.

How does Belsomra compare with Dayvigo and Quviviq?

Belsomra was the first FDA-approved orexin receptor antagonist for insomnia in the United States. It now competes with Dayvigo, or lemborexant, and Quviviq, or daridorexant.

Product	Active ingredient	Developer	Market position
Belsomra	Suvorexant	Merck	First major branded orexin antagonist in the U.S.
Dayvigo	Lemborexant	Eisai	Direct branded competitor with differentiated clinical positioning
Quviviq	Daridorexant	Idorsia/Jazz Pharmaceuticals	Newer entrant positioned around sleep maintenance and next-day effects

All three products compete against generic hypnotics, not only against each other. Their commercial performance depends on formulary placement, prior authorization, copay support, physician comfort, and evidence concerning next-day functioning.

Belsomra benefits from longer market experience. Dayvigo and Quviviq benefit from newer launch messaging and the opportunity to target patients who have not responded to earlier hypnotics or who seek an orexin-based alternative.

What generic entry risks exist for Belsomra?

Generic entry would likely produce a sharp decline in net price, followed by volume migration from brand Belsomra to generic suvorexant. The erosion rate would depend on the number of entrants, payer substitution rules, pharmacy benefit manager policies, and whether Merck launches or authorizes a generic equivalent.

A typical small-molecule generic launch can reduce branded market share quickly when the product is prescribed in primary care and lacks a protected delivery system. Belsomra’s four strengths could support continued brand demand among established patients, but the strengths also make broad generic substitution easier once bioequivalence is demonstrated.

The highest-risk period is the first 12 to 24 months after generic entry. Brand revenue could fall materially even if total suvorexant prescriptions remain stable or increase.

What licensing deals and geographic markets affect Belsomra?

Merck has used regional commercialization relationships for certain products, but Belsomra’s economic value remains concentrated in the United States and other developed prescription markets. International revenue is limited by local reimbursement, different insomnia treatment practices, generic competition, and national patent expiry dates.

Geographic patent coverage may vary significantly. U.S. patent rights do not determine entry timing in Europe, Japan, Canada, or other jurisdictions. Local SPCs, patent-term extensions, national invalidity actions, and regulatory data-exclusivity periods must be assessed separately.

What patent litigation and settlements affect Belsomra?

There is no widely reported settlement that has established a major public generic-entry date for Belsomra. The absence of a disclosed settlement leaves the nominal Orange Book patent dates as the principal public reference points, subject to future litigation.

For investors and licensing teams, the critical triggers are:

1. FDA Orange Book additions or corrections.
2. Paragraph IV notices.
3. ANDA litigation filed in federal district court.
4. Inter partes review petitions at the Patent Trial and Appeal Board.
5. FDA approval letters for generic suvorexant.
6. Authorized-generic or brand-retention announcements by Merck.

Key Takeaways

• Belsomra is Merck’s suvorexant-based dual orexin receptor antagonist for insomnia.
• FDA regulatory exclusivity has expired; patent protection remains the principal barrier to generic entry.
• The relevant U.S. patent estate is associated with protection extending into the late 2020s and potentially around 2030 for later claims.
• Merck does not consistently report current Belsomra revenue as a standalone line item.
• The product is commercially durable but not a major contributor to Merck’s consolidated financial results.
• Dayvigo and Quviviq have increased competitive pressure within the orexin antagonist class.
• Generic entry would likely cause rapid net-price and branded-share erosion.
• The FDA Orange Book, Paragraph IV notices, and federal court filings are the decisive public indicators for U.S. loss of exclusivity.

FAQs about Belsomra patents and market outlook

Is generic suvorexant available in the United States?

Belsomra’s five-year new chemical entity exclusivity has expired, but commercial generic availability depends on ANDA approval, patent certifications, litigation, and any negotiated entry date.

Does Belsomra have biosimilar risk?

No. Belsomra is a chemically synthesized small molecule, so the relevant competitive pathway is an ANDA for generic suvorexant, not a biosimilar application.

Can a generic company avoid Belsomra method-of-use patents?

Potentially. An ANDA applicant may use a section viii statement to omit a patented method of use if the remaining label supports approval and does not induce infringement.

Which drug competes most directly with Belsomra?

Dayvigo and Quviviq are the closest branded competitors because they are also orexin receptor antagonists. Generic zolpidem and other low-cost hypnotics remain the largest volume competitors.

What would most increase Belsomra’s value before patent expiry?

The strongest value drivers would be sustained prescription growth, favorable formulary access, higher refill persistence, successful defense of listed patents, and a controlled transition through an authorized generic or other post-expiry strategy.

References

1. U.S. Food and Drug Administration. (2024). Belsomra (suvorexant) prescribing information.
2. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for suvorexant and orexin receptor antagonist patents.
3. Merck & Co., Inc. (2024). Annual report and Form 10-K.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Congress. (2024). Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.

DrugChatter Q&A for BELSOMRA

How much does belsomra cost?
When is belsomra becomign generic?
When will belsomra go generic?
Belsomra patent protection?
Belsomra prescrit en europe?